"The emergence of GLP-1 medications, originally popular in the US, is now a global phenomenon, projected to grow to 31.5 million users by 2035."
"The impact of GLP-1 medications on consumer behavior transcends the healthcare sector, influencing various industries such as food, beauty, tourism, and technology."
"As appetite decreases due to GLP-1 use, consumer patterns undergo significant transformations, affecting lifestyle choices and consumption habits far beyond simple weight loss."
"Industry leaders recognize that the true disruption in advertising is driven by GLP-1 medications rather than emerging technologies like AI or GPT."
GLP-1 medications have seen significant adoption, with 12% of Americans using them for managing conditions like diabetes and 40% for weight loss. Over the past few years, Novo Nordisk reported $50 billion in sales, primarily from the US. Experts predict the user base will grow globally, reaching 31.5 million users by 2035. The influence of GLP-1 extends beyond healthcare into lifestyle choices, shaping consumer behavior across sectors such as tourism, fashion, and food, prompting numerous industries to adapt strategies accordingly.
Read at The Drum
Unable to calculate read time
Collection
[
|
...
]